The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

PMB-CT01, a BAFF-R targeting CAR-T cell therapy, achieved a 100% complete response rate in relapsed/refractory follicular lymphoma patients. The phase 1 PMB-102 study focuses on safety, optimal dosing ...

Follicular lymphoma (FL) is the most common indolent (slow-growing) form of B-cell non-Hodgkin Lymphoma (NHL), accounting for 20% of NHL in the US.1 FL is considered incurable with current ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- ...

It is defined as a lymphoma of follicle center B-cells (centrocytes and centroblasts), which has at least a partially follicular pattern. It is positive for the B-cell markers CD10, CD19, CD20 ...

Learn the types of B-cell lymphoma, and how each one is diagnosed.

“In patients with follicular lymphoma, FT596 has shown comparable efficacy to the three FDA-approved CAR-T cell therapies, but with significantly reduced toxicity,” Ghobadi said.

Key Takeaways Tafasitamab added to lenalidomide and rituximab reduced progression or death risk by 57% in relapsed/refractory follicular lymphoma patients.